Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

AbbVie Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (148)
Cancellation by sponsor (87)
Prescription medicine registration (25)
Australian public assessment report (AusPar) (22)
Designation or determination (7)
Prescription medicine evaluation (2)
Prescription medicine decision summary (1)
Section 14, TGO91 consent (1)

Date

2025 (27)
2024 (26)
2023 (26)
2022 (14)
2021 (14)
2020 (20)
2019 (24)
2018 (14)
2017 (29)
2016 (5)
2015 (19)
2014 (28)
2013 (4)
2012 (4)
2011 (4)
2010 (5)
2009 (4)
2008 (3)
2007 (1)
2006 (4)
2005 (4)
2002 (2)
2001 (1)
1999 (1)
1998 (1)
1997 (1)
1996 (1)
1994 (2)
1991 (5)

Search

Sponsor content

293 result(s) found, displaying 171 to 180

Abbvie Pty Ltd - Bag, medical device, reusable (275356)

13 May 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for Abbvie Pty Ltd - Bag, medical device, reusable.
VIEKIRA PAK paritaprevir/ritonavir/ombitasvir 75mg/50mg/12.5mg tablets and dasabuvir (as sodium salt) 250mg tablets composite pack blister pack Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Abbvie Pty Ltd
VIEKIRA PAK-RBV paritaprevir/ritonavir/ombitasvir 75mg/50mg/12.5mg tab and dasabuvir (Na) 250mg tab and ribavirin 600mg tab, blisters composite pack Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Abbvie Pty Ltd
VIEKIRA PAK-RBV paritaprevir/ritonavir/ombitasvir 75mg/50mg/12.5mg tabs and dasabuvir (Na) 250mg tabs and ribavirin 200mg tabs, bottles composite pack Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Abbvie Pty Ltd
VIEKIRA PAK-RBV paritaprevir/ritonavir/ombitasvir 75mg/50mg/12.5mg tab & dasabuvir (Na) 250mg tab & ribavirin 400mg & 600mg tab, blisters comp pack Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Abbvie Pty Ltd
VIEKIRA PAK-RBV paritaprevir/ritonavir/ombitasvir 75/50/12.5mg tabs & dasabuvir (Na) 250mg tabs in blist & ribavirin 400mg tabs bottle, composite pack Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Abbvie Pty Ltd
VIEKIRA PAK-RBV paritaprevir/ritonavir/ombitasvir 75/50/12.5mg tabs & dasabuvir (Na) 250mg tabs in blist & ribavirin 600mg tabs bottle, composite pack Cancelled under Section 30(1)(c) of the Act

4 February 2019

Cancellation by sponsor

Requested by Abbvie Pty Ltd
AusPAR: Glecaprevir / pibrentasvir

23 January 2019

Australian public assessment report (AusPar)

Australian Public Assessment Report for Glecaprevir / pibrentasvir
Notice for venetoclax (Abbvie Pty Ltd)

29 October 2018

Designation or determination

Provisional approval
Notice for venetoclax (Abbvie Pty Ltd)

29 October 2018

Designation or determination

Orphan drug

Pages

First page
Previous page
…
Page 14
Page 15
Page 16
Page 17
Current page 18
Page 19
Page 20
Page 21
Page 22
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.